{
    "nct_id": "NCT06564142",
    "official_title": "A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER)",
    "inclusion_criteria": "* Diagnosed IgAN, with biopsy confirmation\n* 24-hr proteinuria excretion ≥1.0 g/day or 24-hour uPCR ≥0.75 g/g\n* Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m^2\n* Stable angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARBs) as per protocol specification\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have received any immunosuppressive treatment or procedures (including corticosteroids, oral immunosuppressive agents, B cell or plasma cell targeted therapies, complement targeted therapies, herbal medicines per protocol, and tonsillectomy) within a wash-out period per protocol\n* Rapidly progressive glomerulonephritis with eGFR reduction >50% within 12 weeks of the start of screening\n\nOther protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}